ABVC BioPharma (ABVC) Short Interest Ratio & Short Volume

Short interest is the volume of ABVC BioPharma shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 587,600 shares of ABVC short. 6.77% of ABVC BioPharma's shares are currently sold short. Learn More on ABVC BioPharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.77% of ABVC BioPharma's floating shares are currently sold short.

ABVC BioPharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 587,600 shares, a decrease of 7.8% from the previous total of 637,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

ABVC BioPharma currently has issued a total of 10,850,000 shares. Some of ABVC BioPharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. ABVC BioPharma currently has a public float of 8,680,000 shares.

6.77% of ABVC BioPharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to ABVC BioPharma: Moleculin Biotech, Inc. (1.53%), Oragenics, Inc. (2.07%), Avalo Therapeutics, Inc. (8.07%), Eterna Therapeutics Inc. (1.89%), Monopar Therapeutics Inc. (0.89%), Elevai Labs, Inc. (0.77%), Kintara Therapeutics, Inc. (2.04%), Aeterna Zentaris Inc. (0.53%), Galera Therapeutics, Inc. (6.09%), Imunon, Inc. (3.80%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling ABVC is an investing strategy that aims to generate trading profit from ABVC BioPharma as its price is falling. ABVC shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for ABVC BioPharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ABVC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABVC, twice per month. The most recent reporting period available is May, 15 2024.